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Abstract
Annually, the incidence of brain tumors has slightly increased and also the patient prognosis is still disappointing, especially for
high-grade neoplasms. So, researchers seekmethods to improve therapeutic index as a critical aim of treatment. One of these new
challenging methods is radioimmunotherapy (RIT) that involves recruiting a coupling of radionuclide component with mono-
clonal antibody (mAb) which are targeted against cell surface tumor–related antigens or antigens of cells within the tumor
microenvironment. In the context of cancer care, precision medicine is exemplified by RIT; precision medicine can offer a
tailored treatment to meet the needs for treatment of brain tumors. This review aims to discuss the molecular targets used in
radioimmunotherapy of brain tumors, available and future radioimmunopharmaceutics, clinical trials of radioimmunotherapy in
brain neoplasms, and eventually, conclusion and future perspective of application of radioimmunotherapy in neurooncology
cancer care.
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Introduction
Malignant brain neoplasms are generally classified as primary
neoplasms, originating from the brain parenchyma itself, and
metastatic tumors, raised from the sites other than the brain.
Primary brain tumors are usually categorized according to the
WHO classification (2016) into gliomas and meningioma as
the most common tumors, respectively, and other neoplasms
with fewer frequencies [1]. The most frequent original sites of
the metastatic brain tumor include the lung, breast, and skin
(melanoma).
Although the incidence of these tumors has slightly in-
creased, patient prognosis is still disappointing, especially
for high-grade neoplasms [2, 3]. The standard of care for brain
tumors treatment consists of debulking surgery, radiotherapy,
and chemotherapy in routine clinical practice. However, pa-
tients demonstrate different responses to the treatment and
finally culminate in poor prognosis and death despite applying
the state-of-the-art of medical care. The variable response may
be partially due to intertumoral and intratumoral heterogeneity
which enable tumor cells to resist against across-the-board
treatment for all tumors. Beside, infiltrative characteristics of
brain tumors contribute to tumor recurrence at or close to the
site of a primary tumor after each surgery so that complete
resection of the tumor would be impossible [4].
Therefore, an across-the-board treatment is not fit to these
complex and heterogeneous neoplasms of the brain. The re-
quirements for dealing with these tumors include providing
tailored management by giving the specific drug to the specif-
ic patient based on molecular and genetic properties, where
precision medicine can play a role. Precision medicine can
offer a tailored treatment to meet the needs for treatment of
brain tumors.
In the context of cancer care, precision medicine is exem-
plified by radioimmunotherapy (RIT). This method involves
recruiting a coupling of radionuclide component and a mono-
clonal antibody (mAb) which are targeted against cell surface
tumor–related antigens or antigens of cells within the tumor
microenvironment [5]. This review aims to discuss the molec-
ular targets used in radioimmunotherapy of brain tumors,
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available and future radioimmunopharmaceutics, clinical tri-
als of radioimmunotherapy in brain neoplasms, and eventual-
ly, conclusion and future perspective of application of
radioimmunotherapy in neurooncology cancer care.
Radioimmunotherapy Targets in Glioma
Tumors
Tenascin-C
Tenascin-C (TN-C) is a hexabrachion polymorphic glycopro-
tein of the extracellular matrix (ECM) which is expressed in
physiological and pathological conditions. It is expressed far
and wide in pathological processes including wound healing,
inflammation, and neoplasm pathogenesis as well as transient
physiological expression during embryogenesis and organo-
genesis [6]. In the context of tumor pathogenesis, its crucial
function is to facilitate the migration of tumor cells through
ECM to other parts of the body [7].
Almost 90% of glioma tumors show widespread expres-
sion of TN-C, glioblastomas per se, contrary to the healthy
tissues which express it only to a minor extent [6, 8]. In 2000,
TN-C was found to have immunoreactivity in the tumor ves-
sels and tumor networks of high-grade astrocytomas [9].
Moreover, TN-C deposition in the tumor vessels was higher
in high-grade compared with low-grade astrocytomas [9].
Furthermore, TN-C expression correlated with proliferative
indices, angiogenesis, and progressive growth pattern [9].
Regarding the key role of TN-C in the angiogenesis, prolifer-
ation, migration, and progression of the glioma tumors and the
overexpression of TN-C in them, it seems that targeting TN-C
would be promising as a biological target in the RITof glioma
tumors [10–16]. So far, several antibodies have been devel-
oped against TN-C which are divided into murine monoclonal
antibodies (mAbs) and chimeric antibodies (cAbs). Murine
mAbs against TN-C consist of BC-2, BC-4, 81C6, ST2146,
ST2485, F16, and P12; and cAbs include ch81C6 [11–14, 17,
18]. These antibodies have been investigated under preclinical
trials, and if they turn out to be promising, they would be
translated to clinical trials [19, 16].
Epidermal Growth Factor Receptor
Epidermal growth factor receptor (EGFR) is a transmembrane
protein which works as a receptor for protein ligands belong-
ing to the epidermal growth factor family [20]. Binding of the
specific ligand to the EGFRwould lead to the phosphorylation
of receptor tyrosine kinase and then activate subsequent signal
transduction pathways which are involved in regulation of
cellular proliferation, differentiation, and survival [20].
Moreover, EGFR overexpression is associated with some can-
cers including brain neoplasms [21]. It has been detected in
about 57% of glioblastoma multiforme (GBM) tumors [21].
EGFR has a prominent role in the proliferation and survival of
the tumor cells, and blocking of EGFR interrupts intracellular
signal transduction. Hence, it has gained significant attraction
as a biological target for RIT of brain tumors.
Thus far, two types of drug have been produced to interfere
with EGFR activity which consist of mAbs against EGFR and
tyrosine kinase inhibitors (TKIs) that interfere with EGFR
activation. These monoclonal antibodies include
nimotuzumab, cetuximab, and monoclonal antibody-425 and
the TKIs comprise erlotinib and gefitinib. Both of these drug
types have been investigated in preclinical and clinical trials
[22–31].
Neural Cell Adhesion Molecule
Neural cell adhesion molecules (NCAMs) are cell surface
glycoproteins which comprise Ig-like and fibronectin type
III (FnIII) domains in their structure and belong to the
immunoglobulin (Ig) superfamily. In the central nervous
system (CNS), these molecules are involved in cell group
formation, NCAM-mediated neurite outgrowth, and syn-
aptic plasticity [32, 33]. Since NCAMs have been detect-
ed in several cancers ubiquitously, including brain tumors,
NCAM-based target therapy of these tumors has attracted
considerable attention.
Several monoclonal antibodies have been produced against
NCAM comprised of 131I-UJ13A, 131I-ERIC-1, 90Y-ERIC1,
and have been tested in RIT of brain tumors through preclin-
ical and clinical investigations [34–37].
Glioma Chloride Channels
Back in 1996, Ullrich et al. identified a chloride ion channel
which is ubiquitously expressed by glioma tumor cells and
intriguingly is lacking in the healthy brain tissue [38].
Furthermore, glioma chloride channel (GCC) expression is
associated with tumor grade so that more than 90% of high-
grade glioma tumor and all of GBM tumors express GCC
[38]. Hence, GCC can be used as both a diagnostic marker
and a therapeutic target.
Chlorotoxin (CTX) is a 36-amino acid peptide isolated
from the giant yellow Israeli scorpion venom (Leiurus
quinquestriatus) which successfully inhibits currents
through GCC with about 80% block at 600 nM CTX
[38]. TM-601 is a synthetic form of CTX that is lyophi-
lized, sterile, and pyrogen-free compound. 131I-TM-601
consists of a coupling of TM-601 as targeting agent with
131I as radionuclide therapeutics [39]. This radioconjugate
has passed phase I of clinical trial and the results are
suggesting that phase II is indicated.
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Histone H1
Tumor necrosis therapy is a novel cancer treatment approach
which involves using mAbs or fragments of such to aim at the
intracellular antigens belonging to the necrotic areas of tumor
[40]. Tumor tissues contain areas of necrotic cells which have
pathologically enhanced cell membrane permeability; there-
fore, the selective passage of immunoglobulins into the cells is
possible [40]. Histone H1 is a linker histone which is located
in the nucleus and interacts with the nucleosomal arrays for
more packaging the nucleosomes into a higher-level chroma-
tin structure [41].
This molecule is present ubiquitously in the necrotic re-
gions of brain tumors. Hence, it could be aimed using a mono-
clonal antibody which is equipped with radionuclide payload
[40]. ChTNT-1/B mAb is a genetically engineered chimeric
mAb that specifically attaches to the DNA-bound histone H1
and forms an insoluble and non-diffusible anchor for the
bound mAb [40]. Recently, it is coupled with the radionuclide
131I and has been recruited in the treatment of glioblastoma
tumors which is discussed later in the text [40, 42].
Neurokinin Type 1 Receptor
Neurokinin type 1 (NK-1R) is one of three kinds of mamma-
lian tachykinin receptors family which have belonged to the 7
transmembrane G-protein coupled receptor family. NK-1R
exerts its effect through the activation of phospholipase C,
producing inositol triphosphate [43]. The ligand for MK-1R
is substance P [44]. Regarding the overexpression of NK1-R
in glioma tumors, NK-1R-targeted therapeutics for the treat-
ment of glioma tumors have been developed. Application of
225Ac-DOTA-substance P was promising in preclinical stud-
ies [45]. Late in 2018, Królicki et al. reported promising re-
sults for using 213Bi-DOTA-substance P in recurrent glioblas-
toma [46].
Future Novel Targets
Fibulin-3
Fibulin-3 is an extracellular matrix (ECM) glycoprotein which
is found in the connective tissues physiologically.
Intriguingly, this molecule is lacking in the healthy brain tis-
sue but is expressed by GBM cells and is present in the ECM
of the tumor tissue [47–49]. Interestingly, fibulin-3 can acti-
vate Notch and NF-κB signaling pathways through autocrine
and paracrine routes that have not been described in healthy
tissues [50–52, 47]. Moreover, fibulin-3 augments the ability
of invasion, vascularization, and survival in the tumor-
initiating cell population of GBM tumors which is associated
with poor prognosis and is considered a biomarker for the area
with active progression [51, 53]. Therefore, since the fibulin-3
is a pivotal mediator in the GBM tumors and the high tumor to
background ratio, it is potentially considered an appealing
molecular target to kill tumor cells.
In 2018, Nandhu et al. developed a function-blocking an-
tibody aiming fibulin-3, named mAb428.2, to kill GBM tu-
mor cells in a mouse model [54]. The mice carrying xenograft
subcutaneous or intracranial GBM received mAb428.2 via
either intratumoral or intravenous (iv) injection. The results
were promising, mAb428.2 could bind to the target success-
fully and impede the fibulin-3 to activate ADAM17, Notch,
and NF-κB signaling in GBM cells and eventually slow tumor
growth, invasion, and vascularization, and prolong mouse sur-
vival. Longo et al. reported anti-fibulin-3-targeted therapy of
GBM can intensify anti-tumor inflammatory response [55].
Regarding evidenced studies together, fibulin-3 represents
an attractive biological target to treat these tumors, especially
for RIT of brain tumors where it is coupled with a radionu-
clide. Fibulin-3-based RIT may offer a promising therapeutics
owing to a high tumor to background ratio by which it reaches
tumor tissue with minimal harm to the adjacent healthy tis-
sues. After, nearby tumor cells are in range to be destroyed
through the fire effect of the radionuclide.
Routes of Drug Administration
Systemic Application of Radioconjugates
Although systemic application of the cytotoxic drugs to treat
many solid tumors ensures delivery of therapeutic dose to
tumor tissues, it is not the same for brain tumors. Systemic
drug delivery to the brain tumors has faced several challenges
of which the most significant obstacle is the intact blood–brain
barrier (BBB) owing to barricading the penetration of the
drugs into the brain parenchyma.
However, systemic administration of radiolabeled mono-
clonal antibodies for RIT of brain tumors in principle is pos-
sible. For instance, Emrich et al. achieved a positive therapeu-
tic response following the intravenous (iv) administration of
125I-labeled EGFR-mAb 425 in the treatment of patients who
suffered from high-grade glioma tumors [56]. Zalutsky et al.
who compared the radioconjugate uptake in the tumors
depicted that, following i.v. injection of radioconjugates, the
levels of I31l-labeled 81C6 (tumor-specific mAbs) were five-
fold higher than those of co-injected 125I-labeled 45.6 (tumor-
non-specific mAbs) as control radioconjugate in tissue biop-
sies obtained posttherapeutically. Moreover, they found that
the level of I31l-labeled 81C6 was up to 200 times higher than
that in healthy brain tissue according to the biopsies [57].
Interestingly, Zalutsky et al. investigated dose delivery of
the monoclonal antibodies to the glioma tumor tissues follow-
ing intravenous and intracarotid injection of the radiolabeled
mAb. They concluded that there is no advantage of drug
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delivery between intravenous and intracarotid administration
of the radiolabeled mAb, but the latter may be associated with
carotid cannulation-related complications.
Locoregional Application of Radioconjugates
Locoregional administration of the drug is determined as di-
rect injection of the radiolabeled monoclonal antibody either
into the tumor tissue or into the tumor cyst, or a surgically
created resection cavity (SCRC). This method was the stan-
dard of choice for drug delivery to the glioma tumors, mostly
because it bypasses the BBB as the most challenging physical
barricade against drug penetration to the brain parenchyma.
Other advantages of locoregional administration are high ra-
diation dose to the tumor with minimal systemic toxicity pro-
file and lacking considerable interference with potential hu-
man antibodies against mouse antigen (HAMA).
Locoregional application of the drugs is performed either
with convection-enhanced delivery (CED), or Ommaya reser-
voir. The CED method includes inserting catheters through
which therapeutic design can be administered using constant,
low-positive pressure bulk flow. Preclinical and clinical stud-
ies have showed that CED can offer efficient delivery of ther-
apeutics to considerable volumes of the brain and brain tumor.
However, catheter technology shortcomings and difficulties in
the imaging of delivery have impeded the technique from
being reliable and reproducible. Furthermore, the only com-
pleted phase III study in GBM did not demonstrate a survival
advantage for the patients treated with a trial therapeutic
reached via CED. Improving the development of CED is on-
going, through innovative catheter designs and imaging ap-
proaches that may improve CED to become a much more
effective therapeutic delivery technique [58].
Ommaya reservoir is surgically inserted through tumor re-
section or during a stereotactic process. The reservoir includes
a small elastic silicon reservoir, which is inserted subcutane-
ously and a linked catheter located in the tumor cyst or the
resection cavity. All therapeutics can be administered through
the reservoir straightly into the resection cavity.
Clinical Studies and Discussion
Clinical data of some selected clinical trials have been sum-
marized in Table 1. The most commonly used monoclonal
antibody for the treatment of glioma tumors is bevacizumab
which is a monoclonal antibody against vascular endothelial
growth factor (VEGF) [59]. Bevacizumab was thought to be
the most promising agent than other agents owing to an asso-
ciation with a higher response rate (28–42%) and 6-month
PFS (progression-free survival) (16–43%) [60]. However, al-
though it was associated with improved quality of life and
radiological pseudonormalization of tumor vasculature, it
lacks overall survival benefits (median overall survival of 8–
9 months) [60, 59, 61–65].
Other molecules which are aimed by radioconjugates to
treat glioma tumors include tenascin-C, EGFR, NCAM,
GCC, DNA-bound histone H1, and NK-1R (Table 1). The
older age and lower Karnofsky performance score are associ-
ated with poorer prognosis [66]. So far, clinical investigations
resulted in variable responses of the same tumor entity to the
same treatment which may partly be due to intertumoral and
intratumoral heterogeneity, inhomogeneous patient popula-
tion, and/or presence of resistancemechanisms. The resistance
mechanisms are discussed subsequently.
Resistance to Radioimmunotherapy
Although the mechanisms underlying resistance to the
radioconjugates are poorly understood yet, they possibly in-
clude the inability to pass through the BBB and/or resistance
to the cytotoxic effect of the radiation. Many investigations
report contradicting or low therapeutic responses among pa-
tients treated with a wide variety of radioimmunotherapeutics.
It is suggested that these drugs can cross the BBB sufficiently
and deliver a therapeutic dose intracranially. Therefore, they
destroy tumor cells through interfering with their principal
biological activities.
However, subsequent recurrence could occur as the result
of a reduction of pharmaceutical penetration into the BBB as
the contrast-enhancing volume of tumor is diminished in the
responding patients. Other rationales may include few tiny
parts of the tumor that may be covered by BBB making them
inaccessible, development of compensatory signaling path-
ways that make target inhibition useless, or extension of a
primary resistant colony of tumor cells that eventually result
in tumor relapse.
The intact BBB represents a physical barrier against
radioconjugates to egress from the bloodstream into the brain
parenchyma principally due to their large size, especially in
tumor regions without contrast enhancement on conventional
MR imaging. Gan et al. [67] showed that the radiolabeled
ABT806i could efficiently penetrate into tissues of EGFR-
expressing tumors with BBB disruption. This observation is
suggest ing the fact that deep penetrat ion of the
radioconjugates into tumor tissues is possible where BBB is
disrupted, as it usually occurs in high-grade gliomas.
Expression of the target antigen is an essential requirement
for effective therapy with antibody-based therapeutics. A dif-
ferent response to the same treatment in patients with one
tumor entity indicates that intratumoral and intertumoral het-
erogeneity contribute to the variable expression of the target
antigen and result in the development of drug resistance. For
instance, no therapeutic response to ABT-414 has been
achieved when the prerequisite target antigen EGFRvIII was
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absent [68]. This observation and similar results may intensify
the fact that assessing the expression level of target antigen is
mandatory before initiating a molecular-based target therapy,
particularly in heterogeneous tumors.
Acquired resistance to the cytotoxic payload is another way
in which the tumor cells shield against therapeutics. In other
cancer types (for instance, prostate cancer), tumors with an
almost similar expression level of target antigen may show
various therapeutic responses to the same treatment [69].
The same results were achieved from a preliminary study of
resistance mechanisms to ABT-414 in patients with glioblas-
toma [70].
Regarding the large body of evidence, it is necessary to
note that although the mechanisms of resistance to the
radioconjugates are poorly understood yet, they constitute a
major cause of failure in treatment of high-grade gliomas.
Indeed, a better understanding of molecular characteristics
and interaction of glioma tumors would give us more insight
into determination of resistance mechanism pathways and de-
tection of a more specific target for the treatment.
Future Prospective
According to a large body of evidence, radioimmunotherapy
represents a promising method in the treatment of brain tu-
mors. Radioimmunotherapy provides targeted delivery of po-
tent radionuclide payloads as a distinctive mechanism of ac-
tion by which a large amount of radionuclide is delivered to
the tumor tissues with a minimum of systemic toxicity. This
potential is exemplified using radiolabeled anti-EGFR in pa-
tients suffering from glioblastoma where the patient popula-
tion who are treated with many anti-EGFR agents (such as
TKIs or naked antibodies) have failed to demonstrate thera-
peutic efficacy, but radiolabeled anti-EGFR therapeutics was
promising.
Regarding the heterogeneous genetic and molecular prop-
erties of high-grade gliomas, GBM per se, the combination of
a radionuclide with the antibodies with intrinsic anti-cancer
properties, is a preferred choice through the development of
RIT therapeutics. Another eminent designated antibody char-
acteristic is tumor specificity of the target along with copious
and/or ubiquitous expression of the target antigen. Essential
features of a successful radiolabeled antibody include suffi-
cient binding capacity to the target, uniform distribution of the
drug within the tumor tissue, and lack of binding to healthy
tissues.
As a result of the high specificity of RIT therapeutics, both
inadequate expression of targeted-antigen and resistance to the
radioconjugates, either antibody or radionuclide, would lead
to treatment failure typically. To achieve an ideal radiolabeled
antibody, including specified tumor targeting without system-
ic toxicities, it is necessary to launch customized preclinical
and clinical trials. Foremost of all, improvements in the ca-
pacity to precisely quantify antigen expression in tumor tissue
noninvasively should be prioritized. Accurate targeted-
antigen quantification can serve as a patient selection strategy
at diagnosis, a modality for resistance detection or guidance in
the treatment selection at the progression of disease.
The proofs of preclinical studies indicate that dual-targeted
treatment strategies can result in more successful outcomes in
comparison with each separate targeted approach. The dual-
targeting therapy approach involves using a combination of
targeted therapeutics that aim at two different populations of
tumor cells simultaneously. Interestingly, newly produced
bispecific antibodies are the other types of this approach
[71–74].
However, all the new potential combinatorial approaches
would necessitate robust phase I investigations to ascertain
that the toxicity profile is acceptable and to determine
combination-dosing schedules for future studies.
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